Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $64.34
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 14, 26 |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 25, 26 | Schoenherr Thomas Edward | officer: CEO, Diagnostics | S-Sale | 10,281 @ $85.00 | $873.9K |
| JP Morgan |
| maintain |
| Neutral |
| Neutral |
| Oct 12, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Oct 1, 26 | Guggenheim | maintain | Buy | Buy |
| Sep 11, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Sep 1, 26 | Piper Sandler | upgrade | Neutral | Overweight |
| Aug 31, 26 | Freedom Capital Markets | maintain | Hold | Hold |
| Aug 20, 26 | BTIG | maintain | Buy | Buy |
| Aug 4, 26 | Piper Sandler | maintain | Neutral | Neutral |
| Aug 3, 26 | Stifel | maintain | Hold | Hold |
| Sep 22, 26 |
| Lefkofsky Eric P |
| director, 10 percent owner, officer: CEO and Chairman |
| S-Sale |
| 17,359 @ $76.57 |
| $1.33M |
| Sep 22, 26 | Lefkofsky Eric P | director, 10 percent owner, officer: CEO and Chairman | S-Sale | 79,259 @ $77.29 | $6.13M |
| Sep 22, 26 | Lefkofsky Eric P | director, 10 percent owner, officer: CEO and Chairman | S-Sale | 37,950 @ $78.23 | $2.97M |
| Sep 22, 26 | Lefkofsky Eric P | director, 10 percent owner, officer: CEO and Chairman | S-Sale | 432 @ $78.86 | $34.07K |
| Sep 22, 26 | Lefkofsky Eric P | director, 10 percent owner, officer: CEO and Chairman | S-Sale | 7,394 @ $76.57 | $566.2K |
| Sep 22, 26 | Lefkofsky Eric P | director, 10 percent owner, officer: CEO and Chairman | S-Sale | 33,770 @ $77.29 | $2.61M |
| Sep 22, 26 | Lefkofsky Eric P | director, 10 percent owner, officer: CEO and Chairman | S-Sale | 16,152 @ $78.23 | $1.26M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 23, 2026 | 2026-10-23 09:00:30 | View |
| EFFECT | Oct 21, 2026 | 2026-10-22 00:15:04 | View |
| 424B3 | Oct 21, 2026 | 2026-10-21 16:20:29 | View |
| S-4/A | Oct 20, 2026 | 2026-10-20 16:09:18 | View |
| S-4/A | Oct 2, 2026 | 2026-10-02 16:14:14 | View |
| 4 | Sep 29, 2026 | 2026-09-29 16:15:06 | View |
| 4 | Sep 24, 2026 | 2026-09-24 16:15:10 | View |
| 4 | Sep 18, 2026 | 2026-09-18 21:15:12 | View |
| 4 | Sep 18, 2026 | 2026-09-18 21:15:10 | View |
| 4 | Sep 18, 2026 | 2026-09-18 21:15:08 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | TEM | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -46.9x | -23.2x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -298.0x | EPS est. -0.22 | Elevated |
| Price / Book | 27.1x | 19.8x | Elevated |
| Price / Sales | 8.2x | 15.1x | Discount |
| EV / EBITDA | -138.7x | -42.3x | Elevated |
| Return on equity | -54.7% | — | Weak |
| Gross margin | 64.0% | 48.9% | Above hist. |
| Debt / Equity | 3.25 | 2.00 | Levered |
| Piotroski / Altman Z | 3/9 | Z 3.01 | Safe zone |
Discounted cash flow model
FY2025 · 10-K disclosure
592 daily bars · split adjusted
Stock news · updated daily
Tempus AI is now a higher-conviction Buy after resolving prior concerns on MRD ownership and cash flow, with adjusted EBITDA turning positive. The Personalis acquisition secures MRD capabilities, integrating high-demand data and supporting pharma partnerships, while xT CDx FDA approval enables significant pricing uplift from 2027. The Data and Applications segment maintains robust ~28% growth, with a growing backlog and margins stabilizing despite headline deceleration and compute cost pressures.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus's largest li.
Daily · Wilder smoothing
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | -0.14 | -0.04 | Beat 72.0% | $382.5M |
| May 5, 2026 | -0.21 | -0.13 | Beat 38.1% | $348.1M |
| Feb 24, 2026 | -0.04 | -0.04 | Beat 8.8% | $367.2M |
| Nov 4, 2025 | -0.17 | -0.11 | Beat 36.2% | $334.2M |
| Aug 8, 2025 | -0.23 | -0.22 | Beat 4.3% | $314.6M |
| May 6, 2025 | -0.26 | -0.24 | Beat 7.7% | $255.7M |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 46.57 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 16.08 | Oscillator | Buy |
| Williams %R (14) | -78.85 | Oscillator | Neutral |
| MACD (12, 26, 9) | -1.42 (Hist -1.07) | Oscillator | Strong Sell |
| Average Directional Index (14) | 19.32 (+DI 15.8 / -DI 19.3) | Trend | Neutral |
| EMA 20 | 69.41 | MA | Strong Sell |
| SMA 20 | 71.95 | MA | Strong Sell |
| EMA 50 | 67.53 | MA | Sell |
| SMA 50 | 68.98 | MA | Sell |
| SMA 200 | 56.81 | MA | Strong Buy |